145 related articles for article (PubMed ID: 20671585)
41. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy.
Cho M; Barbazetto IA; Freund KB
Am J Ophthalmol; 2009 Jul; 148(1):70-8.e1. PubMed ID: 19403115
[TBL] [Abstract][Full Text] [Related]
42. Use of fluorescein and indocyanine green angiography in polypoidal choroidal vasculopathy patients following photodynamic therapy.
Windisch R; Windisch BK; Cruess AF
Can J Ophthalmol; 2008 Dec; 43(6):678-82. PubMed ID: 19020634
[TBL] [Abstract][Full Text] [Related]
43. Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy.
Gemmy Cheung CM; Yeo I; Li X; Mathur R; Lee SY; Chan CM; Wong D; Wong TY
Am J Ophthalmol; 2013 Feb; 155(2):295-304.e1. PubMed ID: 23111181
[TBL] [Abstract][Full Text] [Related]
44. [Clinical observation of polypoidal choroidal vasculopathy].
Zou WJ; Wen F; Wu ZF; Huang SZ; Zhang J; Luo GW
Zhonghua Yan Ke Za Zhi; 2011 Jan; 47(1):39-44. PubMed ID: 21418926
[TBL] [Abstract][Full Text] [Related]
45. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.
Ricci F; Calabrese A; Regine F; Missiroli F; Ciardella AP
Retina; 2012 Jul; 32(7):1280-8. PubMed ID: 22218148
[TBL] [Abstract][Full Text] [Related]
46. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.
Chan WM; Lam DS; Lai TY; Liu DT; Li KK; Yao Y; Wong TH
Ophthalmology; 2004 Aug; 111(8):1576-84. PubMed ID: 15288991
[TBL] [Abstract][Full Text] [Related]
47. Photodynamic therapy with or without intravitreal triamcinolone acetonide for symptomatic polypoidal choroidal vasculopathy.
Lai TY; Lam CP; Luk FO; Chan RP; Chan WM; Liu DT; Lam DS
J Ocul Pharmacol Ther; 2010 Feb; 26(1):91-5. PubMed ID: 20148658
[TBL] [Abstract][Full Text] [Related]
48. Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.
Mori R; Yuzawa M; Lee Z; Haruyama M; Akaza E
Graefes Arch Clin Exp Ophthalmol; 2010 Sep; 248(9):1233-9. PubMed ID: 20352440
[TBL] [Abstract][Full Text] [Related]
49. Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy.
Lee MW; Yeo I; Wong D; Ang CL
Eye (Lond); 2009 Jun; 23(6):1417-22. PubMed ID: 18756283
[TBL] [Abstract][Full Text] [Related]
50. Polypoidal choroidal vasculopathy appearing as classic choroidal neovascularisation on fluorescein angiography.
Tamura H; Tsujikawa A; Otani A; Gotoh N; Sasahara M; Kameda T; Iwama D; Yodoi Y; Mandai M; Yoshimura N
Br J Ophthalmol; 2007 Sep; 91(9):1152-9. PubMed ID: 17314148
[TBL] [Abstract][Full Text] [Related]
51. Photodynamic therapy for polypoidal choroidal vasculopathy.
Kumar Chhablani J
Graefes Arch Clin Exp Ophthalmol; 2011 May; 249(5):791; author reply 793. PubMed ID: 20689963
[No Abstract] [Full Text] [Related]
52. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sagong M; Lim S; Chang W
Am J Ophthalmol; 2012 May; 153(5):873-882.e2. PubMed ID: 22265146
[TBL] [Abstract][Full Text] [Related]
53. Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.
Quaranta M; Mauget-Faÿsse M; Coscas G
Am J Ophthalmol; 2002 Aug; 134(2):277-80. PubMed ID: 12140043
[TBL] [Abstract][Full Text] [Related]
54. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
[TBL] [Abstract][Full Text] [Related]
55. Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy.
Mauget-Faÿsse M; Quaranta-El Maftouhi M; De La Marnièrre E; Leys A
Eur J Ophthalmol; 2006; 16(5):695-704. PubMed ID: 17061220
[TBL] [Abstract][Full Text] [Related]
56. Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.
Nakai S; Matsumiya W; Miki A; Honda S; Nakamura M
Jpn J Ophthalmol; 2019 Sep; 63(5):389-395. PubMed ID: 31376050
[TBL] [Abstract][Full Text] [Related]
57. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.
Akaza E; Yuzawa M; Mori R
Jpn J Ophthalmol; 2011 Jan; 55(1):39-44. PubMed ID: 21331691
[TBL] [Abstract][Full Text] [Related]
58. Photodynamic therapy for polypoidal choroidal vasculopathy: baseline perimetric results and visual outcomes.
Imasawa M; Tsumura T; Sekine A; Kikuchi T; Iijima H
Jpn J Ophthalmol; 2009 Nov; 53(6):588-592. PubMed ID: 20020236
[TBL] [Abstract][Full Text] [Related]
59. Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a multicenter study in Hyogo prefecture, Japan.
Honda S; Imai H; Yamashiro K; Kurimoto Y; Kanamori-Matsui N; Kagotani Y; Tamura Y; Yamamoto H; Ohoto S; Takagi H; Uenishi M; Negi A
Ophthalmologica; 2009; 223(5):333-8. PubMed ID: 19478533
[TBL] [Abstract][Full Text] [Related]
60. CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation.
Hayashi H; Yamashiro K; Gotoh N; Nakanishi H; Nakata I; Tsujikawa A; Otani A; Saito M; Iida T; Matsuo K; Tajima K; Yamada R; Yoshimura N
Invest Ophthalmol Vis Sci; 2010 Nov; 51(11):5914-9. PubMed ID: 20574013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
